HUE052857T2 - Levodopat, egy dopamin dekarboxiláz inhibitort és egy COMT inhibitort tartalmazó gyógyászati készítmények, és azok adagolási módszerei - Google Patents
Levodopat, egy dopamin dekarboxiláz inhibitort és egy COMT inhibitort tartalmazó gyógyászati készítmények, és azok adagolási módszereiInfo
- Publication number
- HUE052857T2 HUE052857T2 HUE15838800A HUE15838800A HUE052857T2 HU E052857 T2 HUE052857 T2 HU E052857T2 HU E15838800 A HUE15838800 A HU E15838800A HU E15838800 A HUE15838800 A HU E15838800A HU E052857 T2 HUE052857 T2 HU E052857T2
- Authority
- HU
- Hungary
- Prior art keywords
- inhibitor
- levodopa
- administration
- pharmaceutical compositions
- dopamine decarboxylase
- Prior art date
Links
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 title 2
- 229940123736 Decarboxylase inhibitor Drugs 0.000 title 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 title 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 title 1
- 239000003543 catechol methyltransferase inhibitor Substances 0.000 title 1
- 239000003954 decarboxylase inhibitor Substances 0.000 title 1
- 229960003638 dopamine Drugs 0.000 title 1
- 229960004502 levodopa Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1451034A SE538425C2 (en) | 2014-09-04 | 2014-09-04 | Pharmaceutical compositions comprising levodopa, carbidopa and a comt inhibitor and method of administration thereof |
| SE1550344 | 2015-03-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE052857T2 true HUE052857T2 (hu) | 2021-05-28 |
Family
ID=55440194
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE15838800A HUE052857T2 (hu) | 2014-09-04 | 2015-09-04 | Levodopat, egy dopamin dekarboxiláz inhibitort és egy COMT inhibitort tartalmazó gyógyászati készítmények, és azok adagolási módszerei |
| HUE20200070A HUE066097T2 (hu) | 2014-09-04 | 2015-09-04 | Levodopát, karbidopát és entakapont tartalmazó gyógyászati készítmények |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE20200070A HUE066097T2 (hu) | 2014-09-04 | 2015-09-04 | Levodopát, karbidopát és entakapont tartalmazó gyógyászati készítmények |
Country Status (16)
| Country | Link |
|---|---|
| US (5) | US10071069B2 (cg-RX-API-DMAC7.html) |
| EP (3) | EP4356907A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6622310B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN107072973A (cg-RX-API-DMAC7.html) |
| AU (3) | AU2015312430B2 (cg-RX-API-DMAC7.html) |
| CA (2) | CA2959307C (cg-RX-API-DMAC7.html) |
| DK (2) | DK3782617T3 (cg-RX-API-DMAC7.html) |
| ES (2) | ES2844500T3 (cg-RX-API-DMAC7.html) |
| FI (1) | FI3782617T3 (cg-RX-API-DMAC7.html) |
| HR (2) | HRP20210025T1 (cg-RX-API-DMAC7.html) |
| HU (2) | HUE052857T2 (cg-RX-API-DMAC7.html) |
| PL (2) | PL3782617T3 (cg-RX-API-DMAC7.html) |
| PT (2) | PT3188725T (cg-RX-API-DMAC7.html) |
| RS (1) | RS65337B1 (cg-RX-API-DMAC7.html) |
| SI (2) | SI3188725T1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016036308A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4356907A1 (en) | 2014-09-04 | 2024-04-24 | LobSor Pharmaceuticals Aktiebolag | Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a comtinhibitor and method of administration thereof |
| WO2016083863A1 (en) * | 2014-11-28 | 2016-06-02 | Bial - Portela & Ca, S.A. | Medicaments for slowing parkinson's disease |
| CN107847722B (zh) | 2015-05-06 | 2021-05-18 | 辛纳吉勒公司 | 包含药物粒子的药用悬浮液、用于其配给的装置、以及其使用方法 |
| WO2017039525A1 (en) | 2015-09-04 | 2017-03-09 | Lobsor Pharmaceuticals Aktiebolag | Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor |
| US10874629B2 (en) * | 2016-04-11 | 2020-12-29 | University Of Canberra | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier |
| AU2017299710A1 (en) * | 2016-07-20 | 2019-01-31 | Abbvie Inc. | Levodopa and carbidopa intestinal gel and methods of use |
| EP3275433A1 (en) | 2016-07-29 | 2018-01-31 | Som Innovation Biotech S.L. | Sustained release composition comprising micronized tolcapone |
| JP7257322B2 (ja) | 2017-02-13 | 2023-04-13 | バイエル・アニマル・ヘルス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | プラドフロキサシンを含有する液体組成物 |
| WO2019129120A1 (en) * | 2017-12-28 | 2019-07-04 | Rpxds Co., Ltd | Tolcapone for prevention and/or treatment of obesity and related metabolic diseases |
| KR20250043584A (ko) | 2018-03-23 | 2025-03-28 | 롭서 파마슈티컬스 악티에볼라그 | 신경퇴행성 장애의 치료를 위한 약제학적 조성물의 연속 투여 |
| EP3593819A1 (en) * | 2018-07-10 | 2020-01-15 | Medday Pharmaceuticals | Compositions for therapeutic uses containing 5-htp and carbidopa |
| MX368750B (es) * | 2018-08-31 | 2019-10-15 | Cell Therapy And Tech S A De C V | Composiciones farmaceuticas semisolidas de base oleosa conteniendo pirfenidona para su aplicacion en la reparacion tisular. |
| EP4417258A3 (en) * | 2018-12-18 | 2024-10-30 | Eli Lilly and Company | Dose regimens for use of ly3154207 in the treatment of dopaminergic cns disorders |
| JP7506371B2 (ja) * | 2020-01-20 | 2024-06-26 | 国立大学法人浜松医科大学 | ドーパミン減少抑制剤 |
| CA3174918A1 (en) * | 2020-03-13 | 2021-09-16 | Bial - Portela & Ca, S.A. | Micronised opicapone |
| CN111643493B (zh) * | 2020-05-26 | 2023-01-10 | 上海京新生物医药有限公司 | 一种高浓度左旋多巴制剂及其制备方法及其应用 |
| PL4200280T3 (pl) | 2020-10-07 | 2024-05-20 | Eli Lilly And Company | Pochodne fenylo-3,4-dihydroizochinolin-2(1h)-ylo-etan-1-onu jako dodatnie modulatory allosteryczne receptora dopaminy d1 |
| WO2022158991A1 (en) * | 2021-01-20 | 2022-07-28 | Bial-Portela & Ca., S.A. | Treatment of pain associated with parkinson's disease with opicapone in combination with levodopa |
| WO2025162373A1 (en) * | 2024-01-30 | 2025-08-07 | National Institute Of Biological Sciences, Beijing | Electrophile-containing catechol-o-methyltransferase (comt) inhibitors for targeting the keap1/nrf2 pathway |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9004348D0 (en) | 1990-02-27 | 1990-04-25 | Orion Yhtymae Oy | New use of catechol derivatives and their physiologically acceptable salts and esters |
| SE9203594D0 (sv) | 1992-11-30 | 1992-11-30 | Christer Nystroem | Laekemedel i dispersa system |
| EP1135118A1 (en) * | 1998-11-10 | 2001-09-26 | Teva Pharmaceutical Industries Ltd. | Dispersible compositions containing l-dopa ethyl ester |
| FI109453B (fi) | 1999-06-30 | 2002-08-15 | Orion Yhtymae Oyj | Farmaseuttinen koostumus |
| US20100221321A1 (en) | 2003-02-27 | 2010-09-02 | Innercap Technologies, Inc. | Apparatus And Methods For Delivering A Plurality Of Medicaments For Management Of Co-Morbid Diseases, Illnesses Or Conditions |
| CN1845728B (zh) * | 2003-08-29 | 2013-06-19 | 转化医药公司 | 包含左旋多巴和卡比多巴的药物组合物 |
| WO2005023185A2 (en) | 2003-08-29 | 2005-03-17 | Transform Pharmaceuticals, Inc. | Pharmaceutical compositions and method of using levodopa and carbidopa |
| WO2005099678A1 (en) | 2004-04-06 | 2005-10-27 | Transform Pharmaceuticals, Inc. | Pharmaceutical compositions and method of using levodopa and carbidopa |
| US20060222703A1 (en) | 2005-04-01 | 2006-10-05 | Iprbox Oy | Pharmaceutical composition and preparation method thereof |
| CA2653683A1 (en) * | 2006-05-31 | 2007-12-06 | Solvay Pharmaceuticals Gmbh | Long term 24-hour intestinal administration of levodopa/carbidopa |
| US8741342B2 (en) | 2006-10-30 | 2014-06-03 | Wockhardt Research Centre | Pharmaceutical compositions comprising entacapone, levodopa, and carbidopa |
| PT2252284E (pt) * | 2008-02-06 | 2011-08-23 | Wockhardt Research Center | COMPOSIÇÕES FARMACjUTICAS DE ENTACAPONE, LEVODOPA E CARBIDOPA COM BIODISPONIBILIDADE MELHORADA |
| US20130253056A1 (en) | 2009-05-19 | 2013-09-26 | Neuroderm, Ltd. | Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same |
| PT2432454T (pt) * | 2009-05-19 | 2017-06-12 | Neuroderm Ltd | Composições para administração contínua de inibidores de dopa decarboxilase |
| HUE047841T2 (hu) | 2010-11-15 | 2020-05-28 | Neuroderm Ltd | L-dopa, dopa dekarboxiláz inhibitorok, katekol-o-metil transzferáz inhibitorok folyamatos adagolására szolgáló készítmények |
| WO2012147099A1 (en) | 2011-04-25 | 2012-11-01 | Suven Nishtaa Pharma Pvt. Ltd. | Pharmaceutical compositions of levodopa, carbidopa and entacapone |
| CN105209029A (zh) | 2013-03-13 | 2015-12-30 | 纽罗德姆有限公司 | 帕金森病的治疗方法 |
| EP4356907A1 (en) | 2014-09-04 | 2024-04-24 | LobSor Pharmaceuticals Aktiebolag | Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a comtinhibitor and method of administration thereof |
| SE538425C2 (en) | 2014-09-04 | 2016-06-21 | Lobsor Pharmaceuticals Ab | Pharmaceutical compositions comprising levodopa, carbidopa and a comt inhibitor and method of administration thereof |
| WO2017039525A1 (en) | 2015-09-04 | 2017-03-09 | Lobsor Pharmaceuticals Aktiebolag | Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor |
-
2015
- 2015-09-04 EP EP23219005.8A patent/EP4356907A1/en active Pending
- 2015-09-04 US US15/507,959 patent/US10071069B2/en active Active
- 2015-09-04 ES ES15838800T patent/ES2844500T3/es active Active
- 2015-09-04 PT PT158388009T patent/PT3188725T/pt unknown
- 2015-09-04 SI SI201531474T patent/SI3188725T1/sl unknown
- 2015-09-04 PT PT202000709T patent/PT3782617T/pt unknown
- 2015-09-04 HU HUE15838800A patent/HUE052857T2/hu unknown
- 2015-09-04 DK DK20200070.9T patent/DK3782617T3/da active
- 2015-09-04 FI FIEP20200070.9T patent/FI3782617T3/fi not_active Application Discontinuation
- 2015-09-04 CA CA2959307A patent/CA2959307C/en active Active
- 2015-09-04 HR HRP20210025TT patent/HRP20210025T1/hr unknown
- 2015-09-04 HR HRP20240314TT patent/HRP20240314T1/hr unknown
- 2015-09-04 AU AU2015312430A patent/AU2015312430B2/en active Active
- 2015-09-04 WO PCT/SE2015/050939 patent/WO2016036308A1/en not_active Ceased
- 2015-09-04 DK DK15838800.9T patent/DK3188725T3/da active
- 2015-09-04 ES ES20200070T patent/ES2973289T3/es active Active
- 2015-09-04 EP EP20200070.9A patent/EP3782617B1/en active Active
- 2015-09-04 CA CA3175785A patent/CA3175785A1/en active Pending
- 2015-09-04 SI SI201531992T patent/SI3782617T1/sl unknown
- 2015-09-04 PL PL20200070.9T patent/PL3782617T3/pl unknown
- 2015-09-04 HU HUE20200070A patent/HUE066097T2/hu unknown
- 2015-09-04 CN CN201580050984.7A patent/CN107072973A/zh active Pending
- 2015-09-04 JP JP2017533154A patent/JP6622310B2/ja active Active
- 2015-09-04 EP EP15838800.9A patent/EP3188725B1/en active Active
- 2015-09-04 RS RS20240276A patent/RS65337B1/sr unknown
- 2015-09-04 PL PL15838800T patent/PL3188725T3/pl unknown
-
2018
- 2018-08-03 US US16/054,392 patent/US10786472B2/en active Active
-
2019
- 2019-11-21 JP JP2019210309A patent/JP6889231B2/ja active Active
-
2020
- 2020-08-13 US US16/992,824 patent/US11413262B2/en active Active
- 2020-09-23 AU AU2020239682A patent/AU2020239682B2/en active Active
-
2022
- 2022-01-18 AU AU2022200291A patent/AU2022200291B2/en active Active
- 2022-06-07 US US17/834,839 patent/US12156858B2/en active Active
-
2024
- 2024-10-21 US US18/921,791 patent/US20250041257A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI3188725T1 (sl) | Farmacevtski sestavki, ki vsebujejo levodopo, dopamin dekarboksilazni inhibitor in COMT inhibitor in način uporabe zdravila | |
| IL257521A (en) | Compositions comprising a pi3k inhibitor and an hdac inhibitor | |
| EP3344624B8 (en) | Tyk2 inhibitors and uses thereof | |
| EP3110820A4 (en) | Tyk2 inhibitors and uses thereof | |
| ZA201803485B (en) | Pharmaceutical compositions comprising levodopa amide and uses thereof | |
| EP3331530A4 (en) | Mthfd2 inhibitors and uses thereof | |
| EP3262049A4 (en) | Tyk2 inhibitors and uses thereof | |
| ZA202001074B (en) | Inhibitors of a-amino-b-carboxymuconic acid semialdehyde decarboxylase | |
| IL247668B (en) | Preparations that include dopa decarboxylase inhibitors | |
| SG11201708034SA (en) | Methods of administering glutaminase inhibitors | |
| PL3426243T3 (pl) | Inhibitory dehydrogenazy 3-fosfoglicerynianowej i ich zastosowania | |
| IL258513B (en) | History of quinoxaline and pyridopyrazine as pi3k inhibitors in the cell | |
| IL248785B (en) | Antecedents of ]-n5,1-dimethyl3--oxo-(3,2-dihydro-h1-pyrazol-4-yl)]-methyl-isoxazole-3-carboxamide and pharmaceutical preparations including these antecedents | |
| EP3272742A4 (en) | Histone deacetylase inhibitor, and preparation method and use thereof | |
| IL255530A (en) | Efflux-pump inhibitors and therapeutic uses thereof | |
| IL274701A (en) | Promote drugs, compositions and methods of their use | |
| IL247921A0 (en) | Glutaminase inhibitor compounds, preparations containing them and their uses | |
| EP3237391A4 (en) | Creatine prodrugs, compositions and methods of use thereof | |
| IL252752A0 (en) | Pharmaceutical preparations containing a combination of pyridazine and egfr inhibitor | |
| IL251162A0 (en) | Monoamine oxidase-B inhibitors and rehabilitation | |
| GB201713779D0 (en) | Blood-brain barrier-penetrant dopamine B-hydroxylase inhibitors |